STUDY COMPARING THE COMBINED USE OF AVONEX AND COPAXONE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是确定同时使用干扰素β1a(Avonex)和醋酸格列酮(Copaxone)治疗复发性多发性硬化症(RRMS)是否安全、耐受和有效，而不是只使用一种药物。Avonex的标准剂量是每周一次肌肉注射30微克。标准剂量的Copaxone是每天皮下注射20毫克。这两种治疗方法、Avonex和Copaxone都是食品和药物管理局批准的药物。然而，标准剂量的联合使用并未获得FDA的批准。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine whether it is safe,tolerable and effective to use both interferone beta 1a (Avonex) and glatiramer acetate (Copaxone) for the treatment of relapsing multiple sclerosis (RRMS), rather than using only one agent alone. The standard dose for Avonex is 30 mcg administered once a week into the muscle. The standard dose of Copaxone is 20 mg administered daily under the skin. Both, treatments, Avonex and Copaxone are Food and Drug approved drugs. However, the combined use at their standard doses is not FDA approved.